| Omalizumab treatment and exercise capacity in severe asthmatics - Results from a pilot study. | |
| | |
MedLine Citation:
|
PMID: 20739169 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
BACKGROUND: In patients with moderate to severe allergic asthma, clinical effectiveness of omalizumab, an approved anti-IgE-reacting substance, is usually assessed by pulmonary function testing (PFT), symptom scores and physicians judgement. AIMS: We postulate that cardiopulmonary exercise testing (CPET) may provide an additional option to verify symptomatic changes in patients with allergic asthma. METHODS: Ten consecutive patients with allergic asthma were treated with omalizumab. Prior to and after 16 weeks of treatment all patients underwent PFT and symptom-limited CPET. Results were compared to 10 asthmatic controls without omalizumab medication. Symptoms were assessed according to investigators judgement (IGETE). RESULTS: All 20 patients showed a significantly impaired exercise capacity at baseline [peak oxygen uptake (VO(2)) 71 ± 16% predicted]. In patients with omalizumab, peakVO(2) increased from 13.8 (8.4-21.4) to 16.8 (11.2-23.9) ml/kg/min (p < 0.05), VO(2) at anaerobic threshold increased by 22% [9.8 (3.3-15.2) to 12.3 (6.7-14.4) ml/kg/min (p < 0.05)]. There was no improvement in the controls. The increase in VO(2) was significantly correlated to the improvement in symptoms. All patients revealed dynamic hyperinflation under exercise with a decreasing extent with omalizumab treatment. CONCLUSION: This study suggests that CPET may provide additional and useful tools to assess and verify the individual clinical response to omalizumab treatment. An improvement in exercise capacity can reliably mirror changes in quality of life and IGETE. Patients with omalizumab experience significant improvements in their initially impaired exercise capacity. CPET can be safely accomplished in patients with severe asthma. |
| | |
Authors:
|
Christoph Schäper; Sven Gläser; Stephan B Felix; Annette Gogolka; Beate Koch; Matthias Krüll; Ralf Ewert; Oliver Noga |
Related Documents
:
|
12485319 - Time efficacy of a single dose of montelukast on exercise-induced asthma in children. 893669 - A critical assessment of the roles of circulating hydrogen ion and lactate in the produ... 6783059 - A controlled trial of ketotifen in exercise-induced asthma. 20477279 - Challenge of exercise-induced asthma and exercise-induced bronchoconstriction. 2221489 - Effect of exercise on complement activity. 589779 - Ige, parasites and asthma in tanzanian children. 3977809 - Effect of physical training in cool and hot environments on +gz acceleration tolerance ... 20737239 - Incorporating performance improvement methods into a needs assessment: experience with ... 6994699 - Multifactorial evaluation of hemofiltration therapy in comparison with conventional hem... |
Publication Detail:
|
Type: Journal Article Date: 2010-08-24 |
Journal Detail:
|
Title: Respiratory medicine Volume: 105 ISSN: 1532-3064 ISO Abbreviation: Respir Med Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-12-14 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8908438 Medline TA: Respir Med Country: England |
Other Details:
|
Languages: eng Pagination: 3-7 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Department of Internal Medicine B - Cardiology, Intensive Care, Pulmonary Medicine and Infectious Diseases, Friedrich-Loeffler-Str. 23, D-17475 Greifswald, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Exercise decreases plasma antioxidant capacity and increases urinary isoprostanes of IPF patients.
Next Document: Integration of planar cell polarity and ECM signaling in elongation of the vertebrate body plan.